Morgan Stanley Cardiol Therapeutics Inc. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 99,881 shares of CRDL stock, worth $108,870. This represents 0.0% of its overall portfolio holdings.
Number of Shares
99,881
Previous 59,613
67.55%
Holding current value
$108,870
Previous $57,000
136.84%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CRDL
# of Institutions
42Shares Held
6.71MCall Options Held
37.6KPut Options Held
0-
Tejara Capital LTD London, X03.27MShares$3.56 Million2.06% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD857KShares$934,5520.22% of portfolio
-
Lion Street Advisors, LLC340KShares$370,6270.15% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9293KShares$319,4310.15% of portfolio
-
Pvg Asset Management Corp Golden, CO283KShares$308,9841.46% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $67.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...